22Feb 2023
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age

Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age

The article discusses the results of the phase 2-3 trial of the BNT162b2 vaccine in children aged six months to 4 years. The trial found that a three-dose primary vaccine series was safe, immunogenic, and efficacious, with an observed overall vaccine efficacy of 73.2% against symptomatic Covid-19. In addition, immunobridging success criteria were met in both age groups, with mostly mild to moderate reactogenicity events reported. These findings are important for the urgent need for safe and effective vaccines against Covid-19 in young children.

  • #family health

Like

Save

Share